Implication of β1- and β2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants

Micó, Juan Antonio; Gibert-Rahola, J.; Casas, J.; Rojas, Olga L.; Serrano, M.I.; Serrano, Juan Bautista Vivero

doi:10.1016/s0924-977x(97)00411-2

Cited by 32 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data indicate that both kynurenine/tryptophan and serotonin/tryptophan ratios in the hippocampus were closely regulated by IDO1 activity. This regulatory mechanism appears to have two important functional implications: on the one hand, increased IDO activity lowers the endogenous serotonin level (43), which leads to depression (44) and diminishes the descending inhibition of pain modulation (45,46); on the other hand, increased IDO activity increases kynurenine derivatives such as quinolinic acid, contributing to neurotoxicity and nociception via the interaction with glutamate receptors (47). Therefore, IDO is situated in a key tryptophan metabolic pathway, and alteration of IDO activity results in changes in the content of endogenous kynurenine and serotonin, both of which play a critical role in the mechanisms of pain and depression (Supplemental Figure 2).…”

Section: Figurementioning

confidence: 99%

Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

Kim¹,

Chen²,

Lim³

et al. 2012

J. Clin. Invest.

274

247

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

Kim¹,

Chen²,

Lim³

et al. 2012

J. Clin. Invest.

274

247

View full text Add to dashboard Cite

“…In fact, both α-adrenoreceptor [10] and 5-HT receptor [11] antagonists have been shown to inhibit antidepressantsmediated antinociception. Moreover, both p-chlorophenylalanine and alpha-methyl-p-tyrosine [12] were shown to inhibit antidepressants-mediated antinociception, by depleting respectively central noradrenaline and serotonin system.…”

Section: Central Mechanisms Of Analgesic Action the Monoamine Hypothesismentioning

confidence: 98%

Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants

Coluzzi

Mattia

2005

CPD

View full text Add to dashboard Cite

Antidepressant drugs have been widely used for many years to treat neuropathic pain, despite the rationale for their use was still unclear. We review recent insights into their mechanism of action, focusing on central and peripheral analgesic actions. Beside the traditional monoaminergic hypothesis, other pharmacological actions have been studied: antidepressants interfere with the opioid system, interact with the NMDA receptors, and inhibit ion channel activity. Firm evidence from randomised controlled trials demonstrated that TCAs are the most effective drugs for treatment of different neuropathic pain conditions. They exhibit the lowest number needed to treat compare with all other drugs investigated. SSRIs failed to provide an adequate analgesia, due to their high selectivity. SSRIs are clearly less effective than TCAs (NNT: 6.7 vs 2.4) supporting the hypothesis that a balanced inhibition of noradrenaline and serotonin reuptake is more effective in relieving pain. On the basis of initial results Venlafaxine seems to be the most promising of the newer antidepressants as analgesic. Newer antidepressants show a better side effects profile, but further investigation are warranted to clarify their potential role in management of pain. Neuropathic pain remains a challenging condition to treat, as all currently available drugs fail to achieve adequate pain relief in a significant proportion of patients. TCAs should be currently considered the first choice in treatment of neuropathic pain and the gold standard against which to compare other potential new treatments.

show abstract

“…Other aspects of monoaminergic systems have been implicated in the analgesic action of antidepressants. Beta-adrenoceptors have been demonstrated to mediate the analgesic effects of desipramine and nortriptyline (Mico et al, 1997). TCAs may reduce hyperalgesia but not tactile allodynia because different neuronal mechanisms underlie different manifestations of neuropathic pain (Jett et al, 1997).…”

Section: Antidepressantsmentioning

confidence: 98%

Pharmacological treatments for chronic non-malignant pain

Clark

2000

International Review of Psychiatry

View full text Add to dashboard Cite

A large body of research now supports the use of traditional psychiatric treatments in the management of chronic pain. Pharmacological treatments have proven effective for many different pain syndromes, especially neuropathic conditions. For any specific disease, no single algorithm can dictate the modalities of treatment to be prescribed. Several classes of medications have proven efficacy for the treatment of neuropathic pain. However, the relief provided by these medications is usually incomplete and difficult to predict in advance. The selection of a particular medication, or combination of medications, will depend on multiple factors. The disease itself may change over time such that the efficacy of a treatment is altered, one treatment may be selected over another based on the response to previous treatments, and the patient's psychiatric co-morbidity, temperament, coping skills, and life story cannot be neglected.

show abstract

Implication of β1- and β2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants

Cited by 32 publications

References 38 publications

Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression

Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants

Pharmacological treatments for chronic non-malignant pain

Contact Info

Product

Resources

About